Terezinha Marta Castineiras

Prof. Dr. Terezinha Marta Castineiras

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Science
Verified
Journal Article
Open access
DCDarlan S. Candido
Darlan S. Candido
ICIngra M. Claro
Ingra M. Claro
JJJaqueline de Jesus
Jaqueline de Jesus
William SouzaWilliam Souza
William Souza
FMFilipe Moreira
Filipe Moreira
NFNuno Rodrigues Faria
Nuno Rodrigues Faria
The spread of SARS-CoV-2 in Brazil: Brazil has been hard-hit by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Candido et al. combined genomic and epidemiological analyses to investigate the impact of nonpharmaceutical interventions (NPIs) in the country. By setting up a network of genomic laboratories using harmonized protocols, the researchers found a 29% positive rate for SARS-CoV-2 among collected samples. More than 100 international introductions of SARS-CoV-2 into Brazil were identified, including three clades introduced from Europe that were already well established before the implementation of NPIs and travel bans. The virus spread from urban centers to the rest of the country, along with a 25% increase in the average distance traveled by air passengers before travel bans, despite an overall drop in short-haul travel. Unfortunately, the evidence confirms that current interventions remain insufficient to keep virus transmission under control in Brazil. Science , this issue p. 1255

26 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CVCarolina M Voloch
Carolina M Voloch
RJRonaldo da Silva F Jr
Ronaldo da Silva F Jr
LALuiz G P de Almeida
Luiz G P de Almeida
CCCynthia Chester Cardoso
Cynthia Chester Cardoso
OBOTAVIO JOSE BERNARDES BRUSTOLINI
OTAVIO JOSE BERNARDES BRUSTOLINI
LWLncc- Workgroup
Lncc- Workgroup
In this study, we report the sequencing of 180 new viral genomes obtained from different municipalities of the state of Rio de Janeiro from April to December 2020. We identified a novel lineage of SARS-CoV-2, originated from B.1.1.28, distinguished by five single-nucleotide variants (SNVs): C100U, C28253U, G28628U, G28975U, and C29754U. The SNV G23012A (E484K), in the receptor-binding domain of Spike protein, was widely spread across the samples. This mutation was previously associated with escape from neutralizing antibodies against SARS-CoV-2. This novel lineage emerged in late July being first detected by us in late October and still mainly restricted to the capital of the state. However, as observed for other strains it can be rapidly spread in the state. The significant increase in the frequency of this lineage raises concerns about public health management and continuous need for genomic surveillance during the second wave of infections. Article Summary Line We identified a novel circulating lineage of SARS-CoV-2 in the state of Rio de Janeiro Brazil originated from B.1.1.28 lineage.

24 February 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
ASAna Paula Santos
Ana Paula Santos
GWGuilherme Loureiro Werneck
Guilherme Loureiro Werneck
ADAna Paula Razal Dalvi
Ana Paula Razal Dalvi
CSCarla Conceição dos Santos
Carla Conceição dos Santos
PTPaulo Fernando Guimarães Morando Marzocchi Tierno
Paulo Fernando Guimarães Morando Marzocchi Tierno
FMFernanda Carvalho de Queiroz Mello
Fernanda Carvalho de Queiroz Mello
Evatuate if Bacillus Calmette-Guérin (BCG) vaccine could be used as a tool against SARS-CoV-2 based on the concept of trained immunity. A multicenter, double-blinded, randomized clinical trial recruited health care workers (HCWs) in Brazil. The incidence rates of COVID-19, clinical manifestations, absenteeism, and adverse events among HCWs receiving BCG vaccine (Moreau or Moscow strains) or placebo were compared. BCG vaccine-mediated immune response before and after implementing specific vaccines for COVID-19 (CoronaVac or COVISHIELD) was analyzed. Cox proportional hazard and linear mixed effect modeling were used. A total of 264 volunteers were included for analysis (BCG = 134 and placebo = 130). The placebo group presented a COVID-19 cumulative incidence of 0.75% vs 0.52% of BCG. The Moreau strain also presented a higher incidence rate (1.60% × 0.22%). BCG did not show a protective hazard ratio against COVID-19. In addition, the log (immunoglobulin G) level against SARS-CoV-2 presented a higher increase in the BCG group, whether or not participants had COVID-19, but also without statistical significance. Our results suggest that BCG has a tendency of protection against SARS-CoV-2 and higher immunoglobulin G levels than placebo. The clinical trial was registered at https://clinicaltrials.gov/ (NCT04659941).

15 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RARenata G F Alvim
Renata G F Alvim
TLTulio M. Lima
Tulio M. Lima
DRDanielle A. S. Rodrigues
Danielle A. S. Rodrigues
FMFederico Francisco Marsili
Federico Francisco Marsili
VBVicente B. T. Bozza
Vicente B. T. Bozza
AVAndré M. Vale
André M. Vale
Accurate serological tests are essential tools to allow adequate monitoring and control of COVID-19 spread. Production of a low-cost and high-quality recombinant viral antigen can enable the development of reliable and affordable serological assays, which are urgently needed to facilitate epidemiological surveillance studies in low-income economies. Trimeric SARS-COV-2 spike (S) protein was produced in serum-free, suspension-adapted HEK293 cells. Highly purified S protein was used to develop an ELISA, named S-UFRJ test. It was standardized to work with different types of samples: (i) plasma or serum from venous blood samples; (ii) eluates from dried blood spots (DBS) obtained by collecting blood drops from a finger prick. We developed a cost-effective, scalable technology to produce S protein based on its stable expression in HEK293 cells. Using this recombinant antigen, we presented a workflow for test development in the setting of a pandemic, starting from limited amounts of samples up to reaching final validation with hundreds of samples. Test specificity was determined to be 98.6%, whereas sensitivity was 95% for samples collected 11 or more days after symptoms onset. A ROC analysis allowed optimizing the cut-off and confirming the high accuracy of the test. Endpoint titers were shown to correlate with virus neutralization assessed as PRNT90. There was excellent agreement between plasma and DBS samples, significantly simplifying sample collection, storing, and shipping. An overall cost estimate revealed that the final retail price could be in the range of one US dollar. The S-UFRJ assay developed herein meets the quality requirements of high sensitivity and specificity. The low cost and the use of mailable DBS samples allow for serological surveillance and follow-up of SARS-CoV-2 vaccination of populations regardless of geographical and socio-economic aspects. We hope the detailed guidelines for the development of an affordable and accurate anti-spike SARS-COV-2 ELISA, such as S-UFRJ described here, will stimulate governmental and non-governmental health agencies in other countries to engage in much-needed large-scale studies monitoring the spread and immunity to SARS-COV-2 infection.

22 December 2021 in Microbiology Spectrum
Verified
Journal Article
Open access
ILIsabela de Carvalho Leitão
Isabela de Carvalho Leitão
PCPedro Telles Calil
Pedro Telles Calil
RGRafael Mello Galliez
Rafael Mello Galliez
FMFilipe Romero Rebello Moreira
Filipe Romero Rebello Moreira
DMDiana Mariani
Diana Mariani
LCLuciana Costa
Luciana Costa
In this study, we evaluated mildly symptomatic immunocompetent patients with long-lasting positive rRT-PCR results for SARS-CoV-2. Infectious viruses were successfully isolated in cell cultures from nasopharynx samples obtained 14 days or longer after symptom onset.

7 July 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MAMarianna Agudelo
Marianna Agudelo
FMFrauke Mücksch
Frauke Mücksch
DSDennis Schaefer-Babajew
Dennis Schaefer-Babajew
ACAlice Cho
Alice Cho
JDJustin DaSilva
Justin DaSilva
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a global problem in part because of the emergence of variants of concern that evade neutralization by antibodies elicited by prior infection or vaccination. Here we report on human neutralizing antibody and memory responses to the Gamma variant in a cohort of hospitalized individuals. Plasma from infected individuals potently neutralized viruses pseudotyped with Gamma SARS-CoV-2 spike protein, but neutralizing activity against Wuhan-Hu-1-1, Beta, Delta, or Omicron was significantly lower. Monoclonal antibodies from memory B cells also neutralized Gamma and Beta pseudoviruses more effectively than Wuhan-Hu-1. 69% and 34% of Gamma-neutralizing antibodies failed to neutralize Delta or Wuhan-Hu-1. Although Class 1 and 2 antibodies dominate the response to Wuhan-Hu-1 or Beta, 54% of antibodies elicited by Gamma infection recognized Class 3 epitopes. The results have implications for variant-specific vaccines and infections, suggesting that exposure to variants generally provides more limited protection to other variants.